I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours

Clinical Nuclear Medicine

Volumn 27, Issue 1, 2002, Pages 1-8

  Gerard, S K ^a   Cavalieri, R R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diagnostic Imaging; I 123; I 131; Thyroid Cancer

Indexed keywords

IODINE 123; IODINE 131;

ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOSE RESPONSE; EVALUATION; HALF LIFE TIME; HUMAN; IMAGE QUALITY; RADIOISOTOPE THERAPY; RISK ASSESSMENT; THYROID CANCER; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; NEOPLASM, RESIDUAL; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS; WHOLE-BODY COUNTING;

EID: 0036136922     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200201000-00001     Document Type: Article

References (29)

1. Nuclear imaging in the management of thyroid carcinoma
2. Imaging in thyroid cancer
3. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients
4. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131
5. Partial stunning in thyroid remnant after administration of scanning dose followed by 100 mCi I-131 therapy
6. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I
7. Detection of thyroid remnant/metastasis without stunning: An ongoing dilemma
8. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma
9. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma
10. Stunning effects after a diagnostic dose of iodine-131
11. Does thyroid stunning exist? A model with benign thyroid disease
12. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry
13. Comparison between Iodine-123 (I-123) and iodine-131 (I-131) sodium iodide total body scanning in thyroid cancer patients
14. Comparison of iodine-123 and iodine-131 as a scanning agent for the detection of metastatic thyroid cancer
15. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases
16. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer
17. Scanning dose and the detection of thyroid metastases
18. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers
19. Scanning dose and detection of thyroid metastases
20. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels
21. Value of post-therapy whole body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy
22. The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation: Concise communication
23. Thyroid stunning
24. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I
25. As soon as possible is already too late
26. 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer
27. Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on wholebody scans: Comparison of quantification and visual assessment of thyroid bed uptake
28. Thyroid stunning after 131I diagnostic whole-body scanning